Summary
The fund managers believe that EchoIQ Ltd is positioned for significant growth due to its innovative technology and strong market demand. In their opinion, the company's recent partnerships with key industry players enhance its competitive edge and provide valuable market access. They highlight the importance of EchoIQ's focus on research and development, which is expected to drive future product enhancements and customer satisfaction. Additionally, the fund managers note that the firm’s financial health is robust, with a solid balance sheet and increasing revenue streams. They express confidence in the management team’s ability to navigate market challenges and capitalize on emerging opportunities. Overall, the fund managers consider EchoIQ Ltd a promising investment, particularly for those looking for exposure in the tech sector.
Please note: The completeness, accuracy or current status of the investments referenced are not guaranteed.
Source: Trading View
Commentary From The Managers
Cadence Capital
30 June 2025
$0.22
Summary
- EchoIQ performed strongly after receiving FDA approval in October 2024.
- Integration agreement established with Beth Israel Deaconess Medical Centre, Boston USA.
- Cadence Capital recently reduced its position for a profit but participated in the most recent capital raise.
- Guzman Y Gomez share price has declined since reaching a high of $45 in February 2025.
- The company is trading at a PE multiple of 232x FY25 earnings.
- High expectations for US and Australia expansion.
- Cadence Capital took a short position when the share price turned and has added to the position as the trend continued down.
Text:
Text:
Text:
Summary
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua, ut enim ad minim veniam.
-
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat, sed ut perspiciatis unde omnis iste.
-
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur, at vero eos et accusamus et iusto odio dignissimos.pedita.
Text:
Text:
Text:
Summary
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua, ut enim ad minim veniam.
-
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat, sed ut perspiciatis unde omnis iste.
-
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur, at vero eos et accusamus et iusto odio dignissimos.pedita.
Text:
Text:
Text:
Summary
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua, ut enim ad minim veniam.
-
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat, sed ut perspiciatis unde omnis iste.
-
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur, at vero eos et accusamus et iusto odio dignissimos.pedita.
Please note: The completeness, accuracy or current status of the investments referenced are not guaranteed.
Become a ThesisTracker Pro Member
-
Unlock current and most recent commentary ahead of the crowd
-
Exclusive access to new insights from the investment community
-
Regular alerts to actionable insights from financial professionals
Commentary From The Managers
Cadence Capital
30 June 2025
$0.22
- EchoIQ performed strongly after receiving FDA approval in October 2024.
- Integration agreement established with Beth Israel Deaconess Medical Centre, Boston USA.
- Cadence Capital recently reduced its position for a profit but participated in the most recent capital raise.
- Guzman Y Gomez share price has declined since reaching a high of $45 in February 2025.
- The company is trading at a PE multiple of 232x FY25 earnings.
- High expectations for US and Australia expansion.
- Cadence Capital took a short position when the share price turned and has added to the position as the trend continued down.
Summary
Cadence Capital
30 Nov 2024
$0.26
- Cadence Capital updates its investment thesis on EchoIQ Ltd.
- EchoIQ is a medical technology company utilizing artificial intelligence to identify heart failure.
- Recent positive results from clinical studies reinforce confidence in their technology.
- In November, EchoIQ signed an agreement with Beth Israel Deaconess Medical Centre (BIDMC) in Boston.
- The partnership aims to integrate EchoIQ’s technology for patient identification with aortic stenosis.
- BIDMC conducts about 30,000 echocardiograms annually, providing valuable data on the efficacy of EchoIQ's solutions.
- Cadence Capital continues to hold EchoIQ as it believes in the growth potential stemming from these developments.
Summary
Cadence Capital
30 Sept 2024
$0.23
- Cadence Capital continues to monitor EchoIQ Ltd, a medical technology firm utilizing artificial intelligence for heart failure detection.
- Recent results from two clinical studies revealed an 86% detection rate of heart failure cases without human review.
- With human review, the detection rate improved to 97%, significantly higher than the current 46% rate in standard practices.
- EchoIQ completed an equity raise to support its commercialization efforts, in which Cadence Capital participated.
- The company’s share price saw a 45% increase in September and has continued to perform well into October.
- Recently, EchoIQ’s technology received FDA approval for marketing and use in the USA by healthcare professionals.
Summary
Please note: The completeness, accuracy or current status of the investments referenced are not guaranteed.
Frequently Asked Questions
Who has invested in EchoIQ Ltd (ASX:EIQ)?
Fund managers including Cadence Capital have invested in EchoIQ Ltd (ASX:EIQ).
Why have investment managers invested in EchoIQ Ltd (ASX:EIQ)?
Fund managers are investing in EchoIQ Ltd due to its innovative use of artificial intelligence for heart failure detection, achieving significantly higher identification rates compared to current practices. The company's recent clinical studies demonstrated an 86% detection rate without human review and 97% with human review, far exceeding the 46% rate of existing methods. EchoIQ's technology has received FDA approval, enabling it to be marketed in the USA, and the company has formed strategic partnerships, such as with Beth Israel Deaconess Medical Centre, which enhances its credibility and market potential. Additionally, the positive market response, evidenced by a 45% share price increase in September 2024, further reinforces investor confidence in the company's growth trajectory.
What happened to EchoIQ Ltd (ASX:EIQ)?
There have been no recent updates from fund managers regarding EchoIQ Ltd although fund managers including Cadence Capital have previously commented.